Global urothelial carcinoma treatment market is expected to grow over the forecast period of 2023 and is expected to register a CAGR ~7.8% during the forecast period of 2018–2023.
Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar cancer in other parts of the urinary tract. Hence the urothelial carcinoma treatment market is expected to grow due to increasing prevalence of bladder cancer. Increasing investment in R&D activities to come up with new cancer treatment is also boosting the market for urothelial carcinoma treatment. As various awareness programs are carried out by government and non-government organizations regarding bladder cancer, it is expected to boost the urothelial carcinoma treatment market during the forecast period.
Various factors that can hamper the growth of the market are the presence of the generic drug in the market and the high cost of R&D investment for the development of a new drug for treatment.
Segmentation
The global urothelial carcinoma treatment market has been segmented on the basis of types, treatment, and end-users. Based on type the global urothelial carcinoma treatment is segmented into non-invasive and invasive urothelial carcinoma treatment. On basis of treatment, the market is segmented into immunotherapy, radiotherapy, and chemotherapy. Based on end-user the urothelial carcinoma market is segmented into hospital pharmacy, retail pharmacy, and others.
Key players
Key players for the global urothelial carcinoma treatment market are GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb.
Global Urothelial Carcinoma Treatment Market, by Type
- Non-invasive urothelial carcinoma treatment
- Invasive urothelial carcinoma treatment
Global Urothelial Carcinoma Treatment Market, by Treatment
- Immunotherapy
- Radiotherapy
- Chemotherapy
Global Urothelial Carcinoma Treatment Market, by End-User
- Hospital pharmacy
- Retail pharmacy
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization